<DOC>
	<DOCNO>NCT01712919</DOCNO>
	<brief_summary>The investigator add weekly cetuximab ( c225 ) standard care chemoradiation locoregionally advanced Nasopharyngeal Carcinoma ( NPC ) , evaluate toxicity efficacy new regimen .</brief_summary>
	<brief_title>Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma ( NPC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Nedaplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Pathologically confirm untreated NPC patient locoregionally advanced ( T34 N23 M0 ) 1865 year MRI examination ECOG â‰¤ 2 With write consent Without second cancer Pregnancy With severe disease ( blood , liver , kidney heart disease ) Could stag properly Without write consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Locoregionally advanced nasopharyngeal carcinoma</keyword>
	<keyword>cetuximab</keyword>
	<keyword>chemoradiation</keyword>
</DOC>